| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT06412120 Study Evaluating Safety, Tolerability, and Metabolism of Niraparib |
date change Primary completion pushed: 2029-06-01 -> 2029-08-01 |
| 2026-06-04 | NCT06412120 Study Evaluating Safety, Tolerability, and Metabolism of Niraparib |
date change Completion pushed: 2031-06-01 -> 2031-08-01 |
| 2026-06-04 | NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… |
date change Primary completion pushed: 2025-09-29 -> 2026-06-14 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06412120 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Ovarian Cancer | Recruiting |
| Phase 3 | |||
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed… | Glioblastoma | Recruiting |
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | Recruiting |
| NCT06915025 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/… | Epithelial Ovarian Cancer | Recruiting |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care… | Ovarian Neoplasms | Active, Not Recruiting |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced… | Ovarian Neoplasms | Active, Not Recruiting |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… | Cancer | Active, Not Recruiting |
| NCT03748641 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus… | Castration-Resistant Prostatic Cancer | Active, Not Recruiting |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus… | Metastatic Castration-sensitive Prostate Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Ovarian Carcinosarcoma | Recruiting |
| Phase 2 | |||
| NCT05700721 | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients… | Brain Metastases | Recruiting |
| NCT05183984 | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | Ovarian Cancer | Recruiting |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2… | Breast Cancer | Recruiting |
| NCT04947254 | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the… | Prostate Carcinoma | Recruiting |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease… | SCLC,Extensive Stage | Recruiting |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | Advanced Microsatellite Stable Colorectal Carcinoma | Active, Not Recruiting |
| NCT04221503 | Niraparib/TTFields in GBM | Glioblastoma | Active, Not Recruiting |
| NCT04068753 | Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive… | Recurrent Cervix Cancer | Active, Not Recruiting |
| NCT05870761 | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous… | Recurrent Endometrial Serous Adenocarcinoma | Active, Not Recruiting |
| NCT05335993 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With… | Recurrent Ovarian Cancer | Active, Not Recruiting |
| NCT04701307 | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other… | Lung Small Cell Carcinoma | Active, Not Recruiting |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Stage I Breast Cancer | Active, Not Recruiting |
| NCT04992013 | Niraparib in Tumors Metastatic to the CNS | Metastatic Cancer | Active, Not Recruiting |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… | Ovarian Cancer | Active, Not Recruiting |
| NCT03431350 | A Study of Niraparib Combination Therapies for the Treatment of Metastatic… | Prostatic Neoplasms, Castration-Resistant | Active, Not Recruiting |